

4 August 2015

Daily news and comments on the Life Sciences Sector in ***Europe*** *by The Daily Molecule, part of Van Leeuwenhoeck Institute*

Companies in Today's newsletter:

- ABLYNX (ABLX.BR)
- CELYAD (CYAD.BR, NASDAQ:CYAD)
- MORPHOSYS (MOR.DE)





	4 August 2015	1 mth	3 mth	1yr	YTD
ASX All Ordinaries	5,681.90	2.8%	-2.3%	2.7%	4.6%
Nasdaq Biotech Index	4,005.27	3.3%	10.8%	52.0%	25.0%
Nasdaq Index	4,580.46	3.3%	2.2%	17.2%	8.3%
Dow Jones Index	17,598.20	-0.7%	-2.6%	6.2%	-1.3%
Euro STOXX 50	3,635.40	5.6%	0.0%	18.3%	15.8%



ABLYNX (ABLX.BR) PRICE: EUR 13.50 (+1.4%)

Ablynx announced that it has administered the first dose in the Phase II STEADY study to evaluate the efficacy and safety of its anti-IL-6R Nanobody, ALX-0061, administered subcutaneously in adult patients with moderate to severe, active seropositive SLE, despite receiving the standard-of-care. The study also aims to identify the optimum dose and frequency of administration of ALX-0061 for the next phases of development.

In September 2013, Ablynx and AbbVie entered into a global license agreement, worth up to US$840 million plus double-digit royalties, to develop and commercialise ALX-0061. As part of the agreement, Ablynx is responsible for Phase II clinical development of ALX-0061 in rheumatoid arthritis and systemic lupus erythematosus. This Phase II study in SLE is a multi-centre, randomized, double-blind, placebo-controlled, dose-range finding study. It is expected to enrol approximately 300 subjects in the United States, Europe, South America and Asia, who will be randomly assigned to placebo or one of the four different dose groups of ALX-0061. Subjects will be followed for efficacy up to and including week 48 and for safety up to and including week 58. The study's primary endpoint is the percentage of subjects who achieved a response at week 24 according to the composite BICLA score (BILAG-based Combined Lupus Assessment). This is a broadly accepted, sensitive, clinically meaningful composite measure of SLE disease activity that requires disease improvement across all body systems with moderate or severe baseline activity without concurrent worsening in other body systems or increase in background medication. **Currently, AbbVie has seven drugs in clinical development for Rheumatoid Arthritis to potentially succeed its blockbuster drug Humira (sales 2014: USD 12.5 billion) that will be running off patent between end 2016 (US patent) and 2018 (EU patent). ALX-0061 is one of them. However, we feel that Galapagos' filgotinib is leading in that pack was already reflected by the USD 1.3 billion (plus double digit royalties) partnership deal with GLPG. Filgotinib is also further in its development with Phase II just concluded. Besides, filgotinib is an oral drug, which we believe is more patient friendly delivery compared to iv injection.**

CELYAD (CYAD.BR, NASDAQ:CYAD) PRICE: EUR 51.50 (+2.0%)

Celyad announced that it has completed the injection procedure for the last patient enrolled in CHART-1, its European Phase III clinical trial for its lead cardiovascular disease product candidate, C-Cure. C-Cure is an autologous cell therapy intended to guide



cardiac tissue formation in patients with ischemic heart failure by harvesting the patient's own multipotent stem cells, reprograming these cells into cardiopoetic cells and re-injecting these reprogrammed cells back into the patient. With the final injection procedure completed, Celyad has initiated the nine-month follow-up period for this patient. The Company expects to release the full clinical data set for CHART-1 in the middle of 2016. The CHART-1 (**C**ongestive **H**eart failure C**a**rdiopoietic **R**egenerative **T**herapy) trial is a Phase III clinical trial to evaluate a cellular therapy for the treatment of heart failure. CHART-1 is a patient prospective, controlled multi-centre, randomized, double-blinded Phase III clinical trial comparing treatment with C-Cure to a sham treatment. The trial has recruited 240 patients with chronic advanced symptomatic heart failure in 12 countries in Europe and Israel. The trial is designed to assess the safety and efficacy of C-Cure.The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at nine months post-procedure. C-Cure is Celyad's most advanced product candidate based on its cardiopoiesis platform and is being developed for heart failure indications.

MORPHOSYS (MOR.DE) PRICE: EUR 74.50 (+1.3%)

Morphosys announced that it has signed an agreement to collaborate with G7 Therapeutics on developing therapeutics targeting G protein coupled receptors (GPCRs) and potentially other disease-related transmembrane proteins such as ion channels. Under the terms of the agreement, G7 Therapeutics will generate a set of disease-relevant receptors proposed by MorphoSys. MorphoSys will then apply its proprietary Ylanthia antibody library to discover and develop antibody therapeutics against these receptors. MorphoSys has the right to sublicense to third parties the access to these targets in conjunction with therapeutic antibody candidates. G7 Therapeutics' platforms SaBRE and CHESS create panels of GPCR variants with enhanced stability and versatility. These GPCRs are evolved from populations containing hundreds of millions of variants of an ancestor GPCR, ensuring the identification of the best possible variant for downstream drug discovery applications. This unique technology ensures that the function of the receptor stays fully intact.



The Daily Molecule is a publication of Van Leeuwenhoeck Institute Inc

Marcel Wijma MSc
CEO & Managing Director

Van Leeuwenhoeck Research (US) Inc
244 Fifth Avenue, Suite W204
New York, NY, 10001 USA

Phone US: +1 917 460 6185
Phone NL: +31 684 892 954
m.wijma@leeuwenhoeck.com
www.leeuwenhoeck.com



COMPANY	TICKER	COUNTRY	CUR	PRICE	PERF 1 MTH	PERF YTD	PERF 1 YR	MARKET CAP (M)
AAP IMPLANTATE	AAQ.DE	GERMANY	EUR	2.49	3.3%	8.2%	-8.0%	76.44
ABLYNX	ABLX.BR	BELGIUM	EUR	13.50	17.9%	47.3%	61.7%	733.05
ABIVAX	ABVX.PR	FRANCE	EUR	20.00	-1.7%	-4.8%	-4.8%	192.48
ADDEX THERAPEUTICS	ADXN.SW	SWITZERLAND	CHF	3.00	-3.0%	26.0%	-15.4%	35.10
ALK ABELLO	AKABY.PK	DENMARK	DKK	831.00	6.9%	27.1%	6.4%	7645.20
HYBRIGENICS	ALHYG.PA	FRANCE	EUR	1.55	4.1%	-13.1%	0.0%	45.60
ARGEN-X	ARGX.BR	BELGIUM	EUR	11.00	7.5%	46.3%	33.2%	172.70
ACTELION	ATLN.VX	SWITZERLAND	CHF	143.20	3.3%	24.3%	28.8%	16339.12
BIOFRONTERA	B8F.DE	GERMANY	EUR	2.13	6.3%	-2.7%	-16.7%	47.29
BAVARIAN NORDIC	BAVA.CO	DENMARK	DKK	306.00	1.9%	57.4%	184.0%	8467.02
BIOTEST	BIO3.DE	GERMANY	EUR	27.90	11.9%	-19.9%	-2.1%	1116.00
BIOTIE	BIOZF.PK	FINLAND	EUR	0.23	0.0%	0.0%	-25.0%	106.41
BONE THERAPEUTICS	BOTHE.BR	BELGIUM	EUR	22.00	5.7%	36.9%	36.9%	150.70
BASILEA	BSLN.SW	SWITZERLAND	CHF	105.60	-9.8%	15.8%	9.3%	1128.86
CELYAD	CYAD.BR	BELGIUM	EUR	51.50	13.7%	46.8%	28.2%	364.11
CELLECTIS	ALCLS.PA	FRANCE	EUR	32.40	7.2%	145.1%	173.9%	
NICOX	COX.PA	FRANCE	EUR	1.82	0.0%	-5.7%	-4.2%	207.92
CERENIS	CEREN.PA	FRANCE	EUR	14.09	17.5%	14.4%	14.4%	250.66
CYTOS	CYTN.SW	SWITZERLAND	CHF	0.44	-10.0%	95.7%	73.1%	47.52
EPIGENOMICS	ECX.DE	GERMANY	EUR	5.73	10.7%	3.8%	72.3%	92.20
ERYTECH PHARMA	ERYP.PA	FRANCE	EUR	39.50	23.2%	30.3%	165.4%	270.85
EVOLVA	EVE.SW	SWITZERLAND	CHF	1.72	3.0%	30.3%	42.1%	564.73
EVOTEC	EVT.DE	GERMANY	EUR	3.51	5.2%	-8.8%	-9.7%	461.35
GENMAB	GEN.CO	DENMARK	DKK	655.00	10.3%	72.0%	191.0%	37315.35
STALLERGENES	GENP.PA	FRANCE	EUR	57.20	9.5%	16.2%	4.5%	792.79
GALAPAGOS	GLPG.BR	BELGIUM	EUR	57.29	18.2%	252.3%	279.2%	1735.89
GRIFOLS	GRF.MC	SPAIN	EUR	40.59	10.7%	20.0%	18.2%	5305.52
GENTICEL	GTCL.BR	BELGIUM	EUR	7.14	1.6%	29.6%	17.3%	109.53
KIADIS	KDS.AS	NETHERLANDS	EUR	12.38	2.5%	0.1%	0.1%	164.78
MAGFORCE	MF6.DE	GERMANY	EUR	5.99	-6.7%	15.8%	-4.0%	143.28
MDXH	MDXH.BR	BELGIUM	EUR	4.80	6.7%	6.7%	31.5%	211.19
MEDIGENE	MDG1.DE	GERMANY	EUR	10.25	-6.5%	160.8%	100.0%	142.78
MOLOGEN	MGN.DE	GERMANY	EUR	4.98	-2.6%	-19.1%	-43.4%	84.51
MORPHOSYS	MOR.DE	GERMANY	EUR	74.50	13.0%	-4.5%	7.1%	1937.00
NANOBIOTIX	NANO.PA	FRANCE	EUR	17.70	1.1%	1.1%	7.9%	237.18
OMEGA DIAGNOSTICS	ODX.L	UK	GBP	17.00	-20.8%	-2.7%	5.3%	18.49
OXFORD BIOMEDICAL	OXB.L	UK	GBP	9.00	0.5%	65.6%	215.4%	230.40
PAION	PA8.DE	GERMANY	EUR	2.69	7.4%	17.5%	2.5%	136.22
UNIQURE	QURE	NETHERLANDS	USD	26.47	-2.8%	74.9%	160.9%	487.84
SANTHERA	SANN.SW	SWITZERLAND	CHF	93.60	4.2%	11.0%	44.1%	466.50
THROMBOGENICS	THR.BR	BELGIUM	EUR	4.96	0.0%	-26.3%	-43.6%	179.01
TIGENIX	TIG.BR	BELGIUM	EUR	0.73	12.9%	25.0%	12.9%	117.15
TRANSGENE	TNG.PA	FRANCE	EUR	2.80	-26.4%	-48.5%	-62.4%	108.16
VALNEVA	VLA.VI	AUSTRIA	EUR	3.94	-3.3%	41.1%	49.1%	292.35
4SC	VSC.DE	GERMANY	EUR	4.03	-10.7%	388.1%	201.5%	204.93
WILEX	WL6.DE	GERMANY	EUR	3.25	-13.4%	90.4%	26.4%	25.42
ZELTIA	ZEL.MC	SPAIN	EUR	4.00	8.1%	40.4%	42.9%	888.80

Source: Van Leeuwenhoeck Institute Inc



Disclaimer
The facts stated and the opinion and prognoses given in this publication are based on data and information considered to be reliable and have been carefully worked into our analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness. Van Leeuwenhoeck Institute. does not accept responsibility or liability in any way in respect to the information stated herein.

Van Leeuwenhoeck Institute does not hold or have positions in securities as referred to in this publication. The views expressed in this publication accurately reflect the analyst's personal views on the subject securities or issuer. Neither the analyst's compensation nor the compensation received by Van Leeuwenhoeck Institute is in any way related to the specific recommendations or views contained in this publication.

Any investments referred to herein may involve significant risk, are not necessarily available in all jurisdictions, may be illiquid and may not be suitable for all investors. The value of, or income from, any investments referred to herein may fluctuate and/or be affected by changes in exchange rates. Past performances are not indicative for future results. Investors should make their own investment decisions without relying on this publication.

Only investors with sufficient knowledge and experience in financial matters to evaluate the merits and risks should consider an investment in any issuer or market discussed herein and other persons should not take any action on the basis of this publication.

Information, opinions or recommendations contained in this publication are submitted solely for advisory and information purposes. The information used and statements of fact made, have been obtained from sources considered reliable, but we neither guarantee nor represent the completeness or accuracy. Such information and the opinions expressed are subject to change without notice. This publication is not intended as an offering or a solicitation of an offer to buy or sell the securities mentioned or discussed.

Van Leeuwenhoeck Institute does not accept any equity compensation. Reports are performed on behalf of the public, and are not a service to any company. The analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests and insure independence.
Periodic Research reports and research notes on this Company are available at our web site:
www.leeuwenhoeck.com